Objective: The aim of this study was to evaluate the differentiation potential of two populations of muscle-derived cells (CD56À and CD56þ) towards chondrogenic phenotype in alginate beads culture and to compare the effect of transforming growth factor beta 1 (TGFb1) on the differentiation process in these populations.
Introduction
Articular cartilage has a limited capacity for healing after trauma and only few long-term treatments are available today, including mosaicplasty, periosteal transplantation, and autologous chondrocyte implantation (ACI) 1e3 . However, these approaches do not result in the regeneration of a fully functional hyaline-like cartilage. Tissue engineering is one of the most promising new approaches to repair articular cartilage. This process involves the use of various cell types, ranged from undifferentiated pluripotent stem cells to welldifferentiated chondrocytes that can act as chondroprogenitor cells 2, 4, 5 . As the limited donor-site capacity to provide a large quantity of chondrocytes is a major impediment to autologous chondrocytes transplantation, much interest has aroused with the use of mesenchymal stem cells (MSCs) derived from bone marrow and other connective tissues, which have the potential to differentiate into chondrogenic lineage 4e6 . In light of its availability, skeletal muscle is an attractive source of cells for use in cartilage tissue engineering because it is the largest organ in the body and only a minimally invasive procedure is required to harvest the tissue via muscle biopsy. Muscle has been extensively investigated as a potential source for isolation of pluripotent stem cells that can differentiate into various lineages, including myogenic, hematopoietic and osteogenic 7e10 . The cellular heterogeneity of skeletal muscle has been pointed out. This diversity has been mainly described in rodent models, the human counterpart being less studied 11e16 .
Myogenic commitment in human has been ascribed to satellite cells and myoblasts, mesoangioblasts, pericytes, myo-endothelial cells, CD34þ/CD133þ cells 17e20 . The differentiation towards specific structures has been observed in dedicated media (chondrocyte-, osteocyte-, and adipocyte-like cells) but it was not always related to an identified cellular progenitor 11,12,15,18,21e24 . These adipogenic, osteogenic and chondrogenic differentiation abilities, however, are one hallmark of MSCs 25 . Concerning chondrogenic differentiation, it has been reported that the use of mice muscle-derived stem cells implantation to repair articular defects improved the healing of the defect, by inducing hyaline cartilage formation with an efficiency equivalent to chondrocyte transplantation 26, 27 . However, species-specific differences in protein functions or cascades made difficult the extrapolation of pathways described in rodents to the human situation.
Several methodologies have been developed to prepare muscle cells. Explants and single fiber cultures allowed studying the biology of satellite cells and of their progeny 12, 14, 28 . Enzymatic dissociation followed by cell sorting, cell cloning, immunomagnetic selection, culture in a specific medium, allowed the preparation of human myogenic cells in view of their clinical use 15,29e36 . Then, taking advantage of a standardized large-scale methodology for preparation of human muscle cells, some of the main cell populations were discovered and selected from the onset of cell culture. The two main populations identified and separated were differentiated by expression of CD56þ, or its absence. Human satellite cells, proliferating myoblasts, myotubes, and fibers undergoing regeneration express the CD56 antigen, equivalent to neural cell adhesion molecule (N-CAM) 11,15,32,37e40 . This marker shows early specificity in human skeletal muscle. The antigen being extracellular, the use of antibodies linked to fluorophores allows the recognition, and further sorting if any, by flow cytofluorimetry (FACS) 41e44 . An anti-CD56 Ab (BectoneDickinson) is validated for the routine use in clinical practice, and a dedicated kit based on immunomagnetic separation of labelled beads is available for use in humans (Miltenyi). CD56 labelling was used for producing and validating human myogenic cells in the context of several clinical trials 12, 44, 45 .
The aim of this study was to determine chondrogenic differentiation abilities of these cell populations. For this purpose, differentiation was induced by shifting from the myogenic growth medium towards specific conditions dedicated to chondrogenesis, corresponding to alginate beads culture with a chondrogenic medium containing dexamethasone and ascorbic acid. As the administration of TGFb1 can enhance cartilage healing, its influence on the differentiation process was also investigated 46e48 . We then showed that both subpopulations (CD56þ and CD56À) have the capacity to differentiate into chondrogenic lineage in vitro when cultured in alginate and TGFb1 enhances the process. However, it also delays hypertrophic markers' synthesis, particularly concerning CD56À cells.
Material and methods

SOURCE OF HUMAN MUSCLE BIOPSIES
Muscle biopsies were obtained in the context of pre-clinical and clinical trials. They were also obtained through the Tissue Bank for Research of the French Association against Myopathies (AFM) who harvested them as res nullus in the context of orthopaedic surgery and consisted in 0.3e1.6 g specimen. The patients were free of muscular pathologies. Muscle biopsies were transmitted as fresh tissue kept at 4 C in Dulbecco's Modified Eagle Medium (DMEM, Invitrogen, Cergy-Pontoise, France) supplemented with gentamicine (50 mg/ml, Panpharma, Fourgè res, France). One gram of fresh muscle yields approximately 500,000 mononucleated cells.
MUSCLE CELLS CULTURE SET UP AND EXPANSION
The methodology has been previously described 32, 49 . Briefly, the fresh biopsies were washed and finely minced using scissors. The muscle fragments were digested using collagenase (Roche, Meylan, France), then trypsineethylen diamine tetraacetic acid (EDTA) (Hyclone, Brebiè res, France). The cell suspension was filtered through 100 then 40 mm cell strainers, pelleted and seeded (density of 2000e5000 cells/cm 2 ). The proliferation medium contained: 80% modified custom-made modified Czapek Dox broth (MCDB) medium (Hyclone), 20% defined fetal bovine serum (FBS) (Hyclone), gentamicine (50 mg/ml, Panpharma), 10 ng/ml human recombinant basic fibroblast growth factor (bFGF) (R&D systems, Lille, France), 10 À6 M dexamethasone (Merck, Fontenay-sous-Bois, France). The medium was changed on the following day to remove tissular and cellular debris. Adherent cells were settled for 6e8 days, then the cells were harvested by trypsinization and expanded before reaching 80% confluency. The cells were grown in this medium for two to three passages, then shifted towards the classical MSCs proliferation medium for one or two passages (alpha-MEM supplemented with 20% FBS, 10 À6 M dexamethasone, 50 mg/ml gentamicine). The cells were used for differentiation assays on passages three to four at which they had undergone 8e12 divisions.
CYTOFLUORIMETRY CHARACTERIZATION AND QUANTIFICATION
The CD56 antigen (N-CAM) was used as a marker of myogenic cells 32 . Muscle derived cells (MDCs) were detached by short incubation in trypsineEDTA (5 min, 37 C), resuspended in phosphate buffered saline (PBS), and labelled for 15 min at 4 C with the anti-CD56 monoclonal antibody, conjugated with phycoerythrin (PE) (BectoneDickinson, BD, Le Pont-de-Claix, France). Nonspecific fluorescence was determined using appropriate conjugated negative isotype control (BD). Cells were washed with PBS and suspended under 200 ml, then analyzed by FACS (Facscalibur, BD) using the Cell Quest software. At least 10 4 events were analyzed. The whole cell population was visualized using a dot plot representation [(forward scatter (FSC) vs side scatter (SSC)] and the cell labelling was quantified using the density plot representation [FSC vs fluorescence axis-2 (FL2)].
SELECTION OF POPULATIONS USING MAGNETIC MICROBEADS
The CD56þ cells were positively selected using ferrite microbeads linked to the CD56 antibody (Miltenyi Biotec, Paris, France). The selection was performed according to the manufacturer instructions, except for the volume of microbeads that was twice that recommended. The buffer contained PBS (90%), human serum albumin (LFB, Les Ulis, France; 5% in volume, 1% final concentration) and anticoagulant buffer ACD (Maco-Pharma, Lille, France). Briefly, cells were washed, incubated for 15 min at 4 C with buffer (40% volume) and beads (60% volume), washed with 10 times the buffer volume, centrifuged. Cells were suspended in 500 ml buffer, loaded on the column inserted in the magnet. The negative fraction was eluted, then the magnet was removed and the positive fraction was eluted. Once separated, both populations were kept for differentiation analysis. Cells were washed, centrifuged, counted and an aliquote was reserved for FACS analysis of the purity. Typically, fractions enriched up to 97% were obtained using a single passage onto the LS columns.
HUMAN ARTICULAR CHONDROCYTES (HACs) CULTURE
Articular cartilage was obtained from femoral heads of patients undergoing joint arthroplasty and then cut into small shavings before digestion at 37 C with pronase E (4 mg/ml in PBS, 45 min, SigmaeAldrich, Saint Quentin-Fallavier, France) and Clostridium hystoliticum collagenase (1 mg/ ml, overnight, SigmaeAldrich) in DMEM containing 10% fetal calf serum (FCS, Invitrogen Life Technologies), penicillin (100 IU/ml, Roger Bellon, Alfortville, France), erythromycin (100 mg/ml, Qualimed, France) and fungizone (0.25 mg/ml, Serva, France). The cell suspension was filtered through a 70 mm-mesh nylon, centrifuged, counted and seeded at 3 Â 10 4 cells/cm 2 in plastic vessels. Chondrocytes were grown in DMEM þ 10% FCS and harvested at confluency.
CHONDROGENIC DIFFERENTIATION CULTURE
MDCs were resuspended in sodium alginate (5 Â 10 6 cells/ml). Beads were then formed by slowly dispensing droplets of the alginate cell suspension from a 22-gauge needle into a 100 mM CaCl 2 solution. After washes with 0.15 M NaCl, the beads were rinsed with a incomplete chondrogenic medium (ICM), corresponding to DMEM with antibiotics, 100 nM dexamethasone, 50 mg/ml ascorbic acid-2-phosphate, 40 mg/ml proline, 1 mM sodium pyruvate and a 1:100 dilution of Insulin Transferrin Selenium supplement (Sigma chemical Co.). All cultures were maintained in ICM or ICM supplemented with rhTGFb1 (10 ng/ml, R&D system) for 21 days and the medium was changed every 2 days. Three experiments from three different donors were performed with both cell types.
After culture, some beads were rinsed with PBS and fixed 2.5 h in 2.5% glutaraldehyde and then, directly frozen in Tissue tech OCT medium in liquid nitrogen. The other beads were dissolved in 55 mM sodium citrate/150 mM NaCl and centrifuged. The pellet served for RNA and protein extractions.
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REAL-TIME REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION (RT-PCR)
Total RNA was extracted using Trizol reagent (Invitrogen). Two micrograms of DNase I-treated RNA were reverse transcribed into cDNA using the High Capacity cDNA Archive kit (Applied Biosystems, Courtaboeuf, France). The cDNA samples were used in real-time PCR analysis, using primers designed with the Primer Express software, SYBR Green PCR Master Mix and the ABI Prism 7000 SDS apparatus (Applied Biosystems), as previously described 50 .
18S RNA was used as a reference gene. Primer sequences used: COLIIA þ COLIIB: Forward GGTC CTG CTG GCC CAA CT/Reverse AGG GAC CCA TAG GAC CTT GTG; COLIIA: Forward CGG GCAG AGG TAT AAT GAT AAG GA/Reverse GTC CCA GTG TCA CAG ACA CAG ATT; AG GRECAN: Forward AGT GGT CAA ACT CCA GAA GTA AAT GG/Reverse GAT GGG CCA CTT CCA ATG TCT; CBFA: Forward GTA CAG CTT TAA GGA TTC CCT CAA TTC/Reverse TTGCTAATGCTTCGTGTTTCCA; 18 S: Forward: CGG CTA CCA CAT CCA AGG AA; Reverse: GCT GGA ATT ACC GCG GCT. Bars represent means AE S.E.M. of three different samples. Statistical significance was assessed using the Student's t test (n ¼ 3): *P < 0.05; **P < 0.01; ***P < 0.001.
ALCIAN BLUE STAINING AND IMMUNOHISTOCHEMISTRY (IHC)
Frozen beads were sectionned (10 mm). For alcian blue staining, sections were rinsed with 0.1 N HCl to decrease the pH to 1.0, stained 10 min with Alcian blue (Sigma) in methanol and washed twice with 0.1 N HCl to remove nonspecific staining.
For IHC, sections were fixed in 4% paraformaldehyde and pre-digested for 1 h at room temperature with chondroitinase ABC (5 U/ml in distilled water) to allow the retrieval of glycoaminoglycan (GAG) staining. Then, sections were incubated with anti-human aggrecan core protein (ACP) primary antibody (Novotec, Lyon, France). Immunostaining was detected using fluoresceine iso thio cyanate (FITC)-conjugated anti-rabbit IgG secondary antibody (Tebubio Santa Cruz Biotechnology, Inc., Le Perray-en-Yvelines, France). Nuclei were counterstained with propidium iodide. Non-immune rabbit serum was used for a negative control. At least five beads from three different cultures were observed and only representative one is shown in figures.
WESTERN-BLOT ANALYSIS
The cells were lysed in radio immuno precipitation assay (RIPA) buffer (50 mM TriseHCl lysis buffer pH 7.5 containing 1% NP-40, 150 mM NaCl, 1 mM ethylene glycol tetraacetic acid (EGTA) and protease inhibitors: phenylmethanesulphonylfluoride (PMSF) (1 mM), pepstatin A (1 mg/ml), aprotinin (1 mg/ml), and leupeptin (1 mg/ml)). After 30 min on ice, the supernatants were collected by centrifugation and total cellular protein amount was determined by the Bradford's colorimetric procedure (Bio-Rad S.A., Ivry sur Seine, France).
Proteins (15e30 mg) were subjected to sodium dodecyl sulfate poly acrylamide gel electiophoresis (SDS-PAGE) in a 8% polyacrylamide gel (acrylamide:bis at 30:1), under reducing conditions and electrophoretically transferred to polyvinylidene difluoride membrane (NEN Life Sciences Products, Zaventem, Belgium). For ACP detection, samples were treated with 0.5 U/ml of chondroitinase ABC (Sigma), prior to western-blot analysis for 2 h at 37 C. Membranes were incubated with rabbit anti-human type II collagen, rabbit anti-human type I collagen (Novotec), goat anti-human ACP, mouse anti-bactin (Santa Cruz Biotechnology, Inc.) and mouse anti-human type X collagen (Sigma) primary antibodies and then with the appropriate secondary antibodies. The membranes were developed with the ECL Plus chemiluminescence detection kit (Amersham Life Sciences, Orsay, France).
ELECTROPHORETIC MOBILITY SHIFT ASSAYS (EMSA)
Nuclear proteins were extracted using hypertonic buffer, as previously described 50 . The protein amount was determined by the Bradford's colorimetric procedure (Bio-Rad S.A., Ivry sur Seine, France).
Double-stranded oligonucleotides, corresponding to Cbfa1 consensus binding sequences, were 5 0 -labelled with [g-32 P]deoxy adenosine triphosphate (dATP) (NEN Life Science, Zaventem, Belgium) and T4 polynucleotide kinase (Promega, Charbonniè res, France). Nuclear extracts (1.5 mg) were incubated with 5 fmoles of the probe, 2Â specific binding buffer and 1 mg of poly(dG.dC).poly(dG.dC) (Amersham Pharmacia Biotech). Samples were fractionated (1.5 h at 150 V) in an 8% polyacrylamide gel in 0.5Â TBE (45 mM Triseborate, 1 mM Na 2 EDTA) and visualized by autoradiography.
Results
ALCIAN BLUE STAINING AND ACP DETECTION
Undifferentiated MDCs (day 0) or cultured during 3, 7 and 21 days in alginate beads, in ICM alone (ICM) or supplemented with TGFb1 (T), were processed as cryostat sections, and compared to alginate without cell.
For both populations, CD56À ( Fig. 1A) and CD56þ (Fig. 1B) , the alcian blue-positive stain is correlated with the duration of incubation and TGFb1 increased the staining intensity. However, in CD56þ cells, the staining seems to decrease between 7 and 21 days. Immunohistochemical staining of ACP corroborated alcian blue staining.
EXPRESSION OF CHONDROCYTE-SPECIFIC MACROMOLECULES IN MDCs
Chondrogenic markers expression was analyzed by RT-PCR and western-blot (Fig. 2) . Expression in alginate beads was compared to that of undifferentiated cells (C0), corresponding to monolayer culture in expansion medium. HACs were used as positive control of differentiated cells.
CD56À cells
Type IIA collagen mRNA was expressed at 3 days of culture and TGFb1 strongly enhanced the process (Fig. 2A1) . The mRNA level of type IIB collagen was strongly increased by the treatment of TGFb1 at 14 and 21 days (Fig. 2A2) . The protein level of type II procollagen (250 kDa) and a1II chain (90 kDa) was also induced by TGFb1 at 14 and 21 days, which was consistent with the RT-PCR results (Fig. 2A3) . A peak of aggrecan mRNA expression was obtained at 14 days in control cells whereas TGFb1 maintains this expression at least until 21 days (Fig. 2B1 ). By westernblot analysis, we showed that ACP (210 kDa) was poorly detected in undifferentiated cells (C0), whereas it appeared in alginate beads cultures, and clearly enhanced by TGFb1 for each time of culture (Fig. 2B2 ).
CD56þ cells
In this subpopulation, type IIA collagen mRNA profile shows a peak of expression at 3 days in control cells and at 7 days with TGFb1 treatment (Fig. 2C1 ). Type IIB collagen transcript was particularly elevated at 21 days, with a significant enhancement by TGFb1 (Fig. 2C2) , confirmed by western-blot ( Fig. 2C3 ). TGFb1 progressively enhanced ACP expression at both mRNA ( Fig. 2D1 ) and protein level ( Fig. 2D2 ).
EXPRESSION OF TYPE I COLLAGEN, TYPE X COLLAGEN AND Cbfa1 AS HYPERTROPHIC CHONDROCYTE MARKERS IN MDCs
CD56À cells
Procollagen I (190 kDa) was detected in undifferentiated cells. Its expression progressively decreased under TGFb1 as soon as 3 days of culture (Fig. 3A1) .
Type X collagen monomer (%66 kDa) was inhibited by TGFb1 (Fig. 3A2) .
In order to determine whether inhibition of hypertrophic chondrocyte markers involves Cbfa1 pathway, we measured mRNA expression and binding activity of this transcription factor by using the real-time PCR analysis and EMSA. The highest expression and binding of Cbfa1 was observed at 14 days in control cells (Fig. 3B1, B2) . Interestingly, TGFb1 strongly inhibits both expression (14 days) and binding (14 and 21 days) of the transcription factor. 
CD56þ cells
In this subpopulation as well, type I collagen is expressed in undifferentiated cells. Even if a peak of expression is obtained at 3 days, type I collagen expression decreased progressively, mostly under TGFb1 treatment.
Interestingly, the a1(X) monomer was mostly detected in undifferentiated cells (C0). Type X collagen expression was also detected at 7 and 21 days of alginate culture with chondrogenic medium only (Fig. 4A2 ). This expression was inhibited by TGFb1, particularly at 21 days of culture. 1513 Osteoarthritis and Cartilage Vol. 16, No. 12 Regarding Cbfa1 expression and binding activity, TGFb1 diminishes mRNA expression ( Fig. 4B1, 21 days) and binding on Cbfa1 consensus sequence (Fig. 4B2 ). However, TGFb1 produces less decrease than CD56À cells.
Discussion
Recent evidences support the existence of a population of multipotential muscle derived stem cells (MDSCs) able to differentiate into various lineages, including myogenic, hematopoietic, osteogenic, endothelial and neuronal 10,51e53 . However, a limited number of studies have examined the use of muscle-derived stem cells for the treatment of articular cartilage. That is why, we assessed the differentiation in vitro of two subpopulations CD56þ and CD56À, towards chondrogenesis.
As evidence by the results of this study, both subpopulations have the capacity for chondrogenesis in vitro, as indicated by a positive staining for GAGs and up-regulation of chondrogenic markers, suggesting common and shared pathways. Our results further precise and confirm the previous descriptions of chondrogenic-or osteogenic-like structures developed from unselected human muscle cell cultures 15, 18, 22, 23 . Furthermore, when cultured in alginate beads with a chondrogenic medium, MDCs behaviour resembles to the differentiation pathway of the chondroosseous rudiment already observed in human BMSCs, suggesting that CD56þ and CD56À cells, like BMSCs, are capable of undergoing a process reminiscent of endochondral ossification, and could be considered as chondro-progenitor cells 54 . Consequently, on the basis of our data, we were able to define three stages in the process of differentiation as the cells accumulate different elements of the new extracellular matrix. In the stage I, in early differentiated cells (prechondrocytes) there was type I and type X collagens expression. During stage II (chondrocyte maturation), type II collagen increased, aggrecan was enhanced, while type I collagen decreased. Finally, type I and type X collagens are newly synthesized, representing stage III, where cells become pre-hypertrophic.
In most studies, neither type II nor type X collagen, a major product of hypertrophic chondrocyte was detected in MSCs. However, previous reports, performed on MSCs from human bone marrow, have shown the presence of type X collagen in undifferentiated cells as well as its induction prior that of type II collagen when cells underwent chondrogenesis 5, 55 . Here, we detected them in both undifferentiated CD56À and CD56þ cells. MDCs were initially expanded in a proliferating medium containing bFGF, which is widely known to induce type X collagen in several cell types including MCSs. This is probably the reason why type X collagen is present in undifferentiated cells. Type II procollagen is expressed in two splice forms. One of them, type IIA procollagen, which contains an additional 69 amino acid cysteine-rich domain, is present in human prechondrogenic and newly formed cartilage tissues 56, 57 . We thus think that both types of undifferentiated MDCs, CD56þ and CD56À, expressed procollagen IIA and could be considered as prechondrogenic precursors. We can also suppose that chondrocytic cells differentiated from CD56À and CD56þ cells express type IIA procollagen and are immature until a marked reduction of type I procollagen synthesis occurs. Then, prechondrocytes differentiate into mature chondrocytes and the mRNA splice form switches from type IIA to IIB procollagen, as demonstrated in other reports 56 . However, the use of an antibody specific to type IIA procollagen N-terminal propeptide would be necessary to exclude the presence of type IIA procollagen protein at 14 and 21 days of MDCs alginate culture.
As evidenced by the results of this study, culture medium conditions and growth factors are essential to chondrogenic differentiation of MDCs. Of note, the proliferation media used in the present study contained dexamethasone from the onset of culture, which may promote the differentiation pathway. When cells were cultured in alginate with ICM, the synthesis of indicators of chondrogenesis increased significantly. 3-D alginate beads culture has become a relevant model for maintaining chondrocyte phenotype and to study their response to cytokines 58, 59 . Similarly, human MSCs encapsulated in alginate have been shown to undergo chondrogenic differentiation and could be used for in vivo application 48, 60 . Here, we demonstrate that alginate culture of MDCs without TGFb1 addition, led them towards chondrogenesis probably due to dexamethasone and sodium ascorbate, as also evidenced in a previous study by in vivo injection of differentiated MDCs in rat 27 .
Sodium ascorbate can modulate chondrocyte growth and differentiation in monolayer cultures, by increasing type II collagen expression 61, 62 . This involvement in our system to induce chondrogenic markers' synthesis is suggested. However, we also found that alginate culture with ICM only induced increased levels of type I and type X collagens proteins at 21 days, what could be attributed to sodium ascorbate. Indeed, previous reports have demonstrated that high concentration of ascorbate can lead to terminal differentiation, with correlated increase of type X collagen synthesis 63, 64 .
To further investigate the regulation of type X collagen transcription in our culture system, we analyzed the DNAbinding activity of nuclear proteins to a Cbfa1 consensus sequence. Indeed, among the few transcriptional determinants specifying hypertrophic chondrocyte-specific type X collagen expression which have been identified to date, the runt domain transcription factor Runx2/Cbfa1 is one of the most important. Several Runx2 modulated target genes have been found in osteoblastic and chondrocytic cells 65e70 . Among them, Runx2 can directly transactivate Col10a1 promoter, both in vitro and in vivo, through putative Runx2 binding sites 71 . Moreover, the location of these sites in the distal promoter is in agreement with the presence of positive regulatory elements in the corresponding 5 0 positions of the human promoter 72 . Runx2 is also required for differentiation of MSC into the osteoblast lineage 73 . Indeed, Runx2-null mice do not have bone and, accordingly, Runx2 has been demonstrated to transactivate genes highly expressed in osteoblasts, including osteocalcin and type I collagen 74 . Furthermore, the Runx2/Cbfa1 pathway would be involved in the differentiation process leading from myogenesis to osteogenesis 75 . In our study, proteins binding activity on Runx2 consensus binding sequence was found up-regulated in untreated cells, suggesting a potential role of Runx2 as inducer of type I and type X collagens expression in MDCs cultured in control conditions. Therefore, combination of alginate and appropriate medium was found sufficient to induce chondrogenesis of CD56 MDCs but could also lead to terminal differentiation. Using TGFb1, we further confirm its importance not only in enhancing the chondrogenesis, but also in maintaining the chondrogenic phenotype. TGFb1 is known to play critical roles in the regulation of chondrogenic events during embryonic skeletal development and to stimulate chondrogenesis of MSCs 46e49, 76 . For both cell types studied, we showed that TGFb1 enhances GAGs deposition, aggrecan and type II collagen synthesis. Moreover, type I and type X collagen proteins' synthesis was inhibited, particularly in CD56À cells, suggesting that chondrocytes did not demonstrate significant hypertrophy. This data was further supported by the inhibition of nuclear proteins binding activity on Cbfa1 consensus sequence in TGFb1-treated MDCs at 14 and 21 days of culture, which could explain TGFb1induced down-regulation of type I and type X collagens expression.
Findings concerning TGFb1 effect on MSCs are still controversy and underline the fact that its effect on MSCs' osteoblastic or chondrogenic differentiation depends on culture conditions and doses used. In vitro experiments demonstrated that its use may lead to hypertrophic differentiation, with subsequent formation of inadequate tissue instead of hyaline cartilage 48, 77 . However, TGFb1 has also been shown to inhibit terminal differentiation of chondrocytes 78, 79 . This reinforces our conclusions that TGFb1 administration may be more effective in preserving chondrocyte phenotype of MDCs cultured in alginate.
Conclusions
This study allows to a better understanding of chondrogenic differentiation of selected populations from expanded human skeletal muscle. Alginate and TGFb1 association promotes the transformation of CD56þ and CD56À cells into chondrocytes. We showed that TGFb1 is important for maintaining chondrogenic phenotype by repressing terminal differentiation. This point is of interest in view of preparing grafts to repair cartilage, with lower any risk of tissue calcification after transplantation. Thus, the mesenchymallike behaviour of human muscle-selected cells and our data further support that skeletal muscle may represent a promising source of progenitor cells, which can be used in clinical setting to improve cartilage healing. Our results strongly suggest the usefulness of CD56À muscle-derived stem cells for articular cartilage repair and regeneration applications.
